222 JACOBS STREET, CAMBRIDGE, MA
Completes Acquisition of Cerevel Therapeutics
Material disclosure
To Acquire Cerevel
Reports Third Quarter 2023 Financial Results and Business Updates
Announces Pricing of $450 Million Public Offering of Common Stock
Earnings Release
Reports Second Quarter 2023 Financial Results and Business Updates
Shareholder votes
Q1
FY 2023 amended
FY 2023
Q3
Q2
FY 2022 amended
FY 2022
Notice of Suspension of Duty to File Reports
Effectiveness Notice
Prospectus filed pursuant to Rule 424(b)(5)
Registration Statement for Securities to be Offered to Employees
Additional Proxy Materials
Definitive Merger Proxy Statement
PRER14A
Definitive Proxy Statement
Statement of Changes in Beneficial Ownership
Amended Schedule 13D - Ownership Report
S-8 POS
Post-Effective Amendment to Registration Statement
PREM14A